IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE

In re:	Chapter 11
Apple Tree Life Sciences, Inc., *et al*.,[1]	Case No. 25-12177 (LSS)
Debtors.	(Jointly Administered)

NOTICE OF AGENDA OF MATTERS SCHEDULED
FOR HEARING ON OCTOBER 19, 2026 AT 2:00 P.M. (ET)

This proceeding will be conducted in-person. All counsel and witnesses are expected to attend unless permitted to appear remotely via Zoom. Please refer to Judge Silverstein's Chambers Procedures (https://www.deb.uscourts.gov/judge-laurie-selber-silverstein) and the Court's website (https://www.deb.uscourts.gov/ecourt-appearances) for information on who may participate remotely, the method of allowed participation (video or audio), Judge Silverstein's expectations of remote participants, and the advance registration requirements.

Registration is required by 4:00 p.m. (ET) the business day before the hearing unless otherwise noticed using the *eCourtAppearances* tool available on the Court's website.

MATTERS GOING FORWARD:

1. Motion of Debtor ATP Life Science Ventures, L.P., for Entry of an Order Confirming Its Rights with Respect to Portfolio Companies [Docket No. 1188 – filed September 30, 2026].

   Response/Objection Deadline: October 7, 2026 at 4:00 p.m. (ET). Extended to October 9, 2026 at 4:00 p.m. (ET). Further extended for Apertor Pharmaceuticals, Inc., Evercrisp Biosciences, Inc., Initial Therapeutics, Inc., Marlinspike Therapeutics, Inc., Nereid Therapeutics Inc., Nine Square Therapeutics, Inc., and Red Queen Therapeutics, Inc. to October 13, 2026 at 4:00 p.m. (ET).

[1] The Debtors in these chapter 11 cases, along with the last four digits of each Debtor's federal tax identification number include: Apple Tree Life Sciences, Inc. (4506); ATP Life Science Ventures, L.P. (8224); ATP III GP, Ltd. (6091); Apertor Pharmaceuticals, Inc. (3161); Initial Therapeutics, Inc. (2453); Marlinspike Therapeutics, Inc. (4757); Red Queen Therapeutics, Inc. (8563); Evercrisp Biosciences, Inc. (4437); Nine Square Therapeutics, Inc. (4503); and Nereid Therapeutics Incorporated (8493). The location of the Debtors' service address in these chapter 11 cases is 230 Park Avenue, Suite 2800, New York, NY 10169.

Related Documents:

A. Notice of Rescheduled Hearing on Motion of Debtor ATP Life Science Ventures, L.P., for Entry of an Order Confirming Its Rights with Respect to Portfolio Companies [Docket No. 1197 – filed October 06, 2026].

Responses/Objections Received:

i. Objection by Apertor Pharmaceuticals, Inc., Evercrisp Biosciences, Inc., Initial Therapeutics, Inc., Marlinspike Therapeutics, Inc., Nereid Therapeutics Inc., Nine Square Therapeutics, Inc., and Red Queen Therapeutics, Inc. to Motion of Debtor ATP Life Science Ventures, L.P., for Entry of an Order Confirming its Rights with Respect to Portfolio Companies [Docket No. 1209 – filed October 13, 2026].

ii. Reply of Debtor ATP Life Science Ventures, L.P. in Support of Its Motion for Entry of an Order Confirming Its Rights with Respect to Portfolio Companies [Docket No. 1210 – filed October 14, 2026].

Status: This matter is going forward.

[*Signature Pages Follow*]

Dated: October 15, 2026
Wilmington, Delaware

Respectfully submitted,

/s/ R. Craig Martin

R. Craig Martin (DE No. 5032)
DLA PIPER LLP (US)
1201 North Market Street, Suite 2100
Wilmington, Delaware 19801
Telephone: (302) 468-5700
Facsimile: (302) 394-2341
Email: craig.martin@us.dlapiper.com

-and-

Gregory M. Juell (NY No. 5420120)
DLA PIPER LLP (US)
1251 Avenue of the Americas
New York, New York 10020
Telephone: (212) 335-4000
Facsimile: (212) 335-4501
Email: gregory.juell@us.dlapiper.com

-and-

Shant K. Eulmessekian (NY No. 6094668)
DLA PIPER LLP (US)
2000 Avenue of the Stars, Suite 400 North Tower
Los Angeles, California 90067
Telephone: (310) 595-3000
Facsimile: (310) 595-3300
Email: shant.eulmessekian@us.dlapiper.com

Counsel to the Fund Debtor